Company Encyclopedia
View More
name
Jupiter Neurosciences
JUNS.US
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson’s disease.
4.729 T
JUNS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jupiter Neurosciences Signs Multiple Material Agreements

    Jupiter Neurosciences has signed multiple agreements with Yorkville to enhance liquidity and financing flexibility. These include a Standby Equity Purchase Agreement and a Registration Rights Agreement, effective from October 24, 2025. The agreements allow Jupiter to sell shares over time and enable resale registration for SEPA shares. Shareholders approved issuances above Nasdaq's 19.99% cap, and the company received a $1.86 million advance. These steps aim to provide flexible access to capital for operations and growth.

    TradingView·
    US
    JUNS
    +3.64%
    TradingView·
    US
    JUNS
    +3.64%

    Jupiter Neurosciences Secures $1.86 Million Second Tranche Financing from Yorkville

    Jupiter Neurosciences Inc. has secured $1.86 million in second tranche financing from Yorkville under a Standby Equity Purchase Agreement (SEPA). The company received the funds on December 23, 2025, following stockholder approval, and issued a second convertible promissory note to Yorkville. The agreement allows Jupiter to direct Yorkville to purchase additional shares of its common stock, subject to SEPA terms. The securities are issued under an exemption from registration under the Securities Act.

    Reuters·
    US
    JUNS
    +3.64%
    Reuters·
    US
    JUNS
    +3.64%

    Jupiter Neurosciences Hosts Live Investor Webinar Showcasing JOTROL and Nugevia Platform

    Jupiter Neurosciences Inc. will host a live investor webinar on January 6, 2026, at 4:15 p.m. ET, featuring Chairman and CEO Chister Rosén. The event will cover the company's scientific platform, clinical development plans, and commercial strategy, including updates on JOTROL™ and the Nugevia™ product line. A live Q&A session will follow. Participants can register online. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    JUNS
    +3.64%
    Reuters·
    US
    JUNS
    +3.64%

    Jupiter Neurosciences Inc. Held Annual Shareholder Meeting

    Jupiter Neurosciences Inc. held its 2025 Annual Meeting of Stockholders on December 19, 2025. Stockholders approved the 2025 Equity Incentive Plan and an amendment to increase authorized shares of common stock from 125,000,000 to 500,000,000.

    Reuters·
    US
    JUNS
    +3.64%
    Reuters·
    US
    JUNS
    +3.64%

    Jupiter Neurosciences to Present at NobleCon21 Emerging Growth Conference

    Jupiter Neurosciences Inc. will present at NobleCon21 on December 2-3, 2025, in Boca Raton, Florida. The management team will also be available for one-on-one meetings with investors. This news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    JUNS
    +3.64%
    Reuters·
    US
    JUNS
    +3.64%
    © 2025 Longbridge｜Disclaimer